The C161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARγ) is associated with risk of coronary artery disease: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 4, 2013, Pages 3101-3112

  Wu, Zhijun ^a   Lou, Yuqing ^a   Jin, Wei ^a   Liu, Yan ^a   Lu, Lin ^a   Lu, Guoping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

C161T; Coronary artery disease; Polymorphism; PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALLELE; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ETHNICITY; GENE; GENE ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HETEROZYGOTE; HUMAN; PPAR GAMMA GENE; PUBLISHING; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK FACTORS;

EID: 84878423669     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2384-3     Document Type: Article

References (43)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD et al (2012) Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125:e2-e220
2. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
3. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI et al (2002) Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 252:247-254
4. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422-430
5. Fisman EZ, Tenenbaum A (2009) A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8:38
6. Kota BP, Huang TH, Roufogalis BD (2005) An overview on biological mechanisms of PPARs. Pharmacol Res 51:85-94
7. Wahli W, Michalik L (2012) PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 23:351-363
8. Huang JV, Greyson CR, Schwartz GG (2012) PPAR-gamma as a therapeutic target in cardiovascular disease: Evidence and uncertainty. J Lipid Res 53(9):1738-1754
9. Fahmi H, Martel-Pelletier J, Pelletier JP, Kapoor M (2011) Peroxisome proliferator-activated receptor gamma in osteoarthritis. Mod Rheumatol 21:1-9
10. Moffett SP, Feingold E, Barmada MM, Damcott CM, Marshall JA et al (2005) The C161- > T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in peroxisome proliferator-activated receptor gamma. Metabolism 54:1552-1556
11. Dongxia L, Qi H, Lisong L, Jincheng G (2008) Association of peroxisome proliferator-activated receptorgamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ J 72:551-557
12. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr et al (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57:e215-e367
13. Joensen AM, Jensen MK, Overvad K, Dethlefsen C, Schmidt E et al (2009) Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. J Clin Epidemiol 62:188-194
14. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM et al (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123:e426-e579
15. Cohn LD, Becker BJ (2003) How meta-analysis increases statistical power. Psychol Methods 8:243-253
16. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826
17. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557-560
19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629-634
20. Ramsey DM, Futschik A (2012) DNA pooling and statistical tests for the detection of single nucleotide polymorphisms. Stat Appl Genet Mol Biol 11: Article 1
21. Peng DQ, Zhao SP, Nie S, Li J (2003) Gene-gene interaction of PPARgamma and ApoE affects coronary heart disease risk. Int J Cardiol 92:257-263
22. Wan J, Xiong S, Chao S, Xiao J, Ma Y et al (2010) PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol 9:13
23. Wang XL, Oosterhof J, Duarte N (1999) Peroxisome proliferator-activated receptor gamma C161- >T polymorphism and coronary artery disease. Cardiovasc Res 44:588-594
24. Liu Y, Yuan Z, Zhang J, Yin P, Wang D et al (2007) PPARgamma gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression. Am Heart J 154:718-724
25. Bluher M, Klemm T, Gerike T, Krankenberg H, Schuler G et al (2002) Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus. Eur J Endocrinol 146:545-551
26. Zhou X, Chen J, Xu W (2012) Association between C1431T polymorphism in peroxisome proliferator-activated receptor-gamma gene and coronary artery disease in Chinese Han population. Mol Biol Rep 39:1863-1868
27. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24:2403-2407
28. Dallongeville J, Iribarren C, Ferrieres J, Lyon L, Evans A et al (2009) Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Res 2009:543746
29. Chao TH, Li YH, Chen JH, Wu HL, Shi GY et al (2004) The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci (Lond) 107:461-466
30. Yilmaz-Aydogan H, Kurnaz O, Kurt O, Akadam-Teker B, Kucukhuseyin O et al (2011) Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem 358:355-363
31. Evangelisti L, Attanasio M, Lucarini L, Sofi F, Marcucci R et al (2009) PPARgamma promoter polymorphisms and acute coronary syndrome. Atherosclerosis 205:186-191
32. Colhoun HM, McKeigue PM, Davey Smith G (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872
33. Whitehead A (2003) Meta-analysis of controlled clinical trials. Wiley, Chichester
34. Attia J, Thakkinstian A, D'Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297-303
35. Hemminki K, Lorenzo Bermejo J, Forsti A (2006) The balance between heritable and environmental aetiology of human disease. Nat Rev Genet 7:958-965
36. Su J, Qi Y, Liu S, Wu X, Lv J et al (2012) Revealing epigenetic patterns in gene regulation through integrative analysis of epigenetic interaction network. Mol Biol Rep 39:1701-1712
37. Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. Trends Genet 20:350-358
38. Salanti G, Sanderson S, Higgins JP (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7:13-20
39. Munafo MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20:439-444
40. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 283:2008-2012
41. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM et al (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528
42. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P et al (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435-440
43. Dragojević JMJMB (2008) Association between Pro12Ala and His477His polymorphisms in PPARG gene and insulin resistance in patients with polycystic ovary syndrome. Biochemia Medica 18:342-350